The MAb Squad: Delivering Covid-19 Monoclonal Antibody Therapy Across a Large Geographic Region

Abstract

Summary Providing access to anti–severe acute respiratory syndrome coronavirus 2–neutralizing monoclonal antibody (MAb) infusions to ambulatory patients with early-onset Covid-19 poses numerous operational challenges to health care systems. Among these include optimizing efficacy through early identification of high-risk patients, ensuring equitable access to disadvantaged populations and across wide geographic regions, preserving access to infusion services for other populations, maintaining adequate infection control, and managing resource constraints. Intermountain Healthcare shares its experience designing and implementing a novel care delivery pathway for MAb therapy to address these challenges within a large integrated health care system. By describing adaptable and scalable solutions, the authors hope to illustrate the real-world feasibility of implementing these promising therapies in health care systems, large and small, to improve patient outcomes and preserve hospital capacity.